Work

Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas

Year: 2021

Type: review

Source: Neurosurgery Clinics of North America

DOI: 10.1016/j.nec.2020.12.008

Authors: Dagoberto Estevez-Ordonez, Gustavo Chagoya, Arsalaan Salehani, Travis J. Atchley, Nicholas M.B. Laskay, Matthew S. Parr, Galal A. Elsayed, Anil K. Mahavadi, Sage P. Rahm, Gregory K. Friedman, James M. Markert

Institutions: University of Alabama at Birmingham, UAB Medicine

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Gateway for Cancer Research, U.S. Food and Drug Administration, National Cancer Institute, Fogarty International Center, National Institute of Neurological Disorders and Stroke

Awards: Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor), A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma., Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor), G4370540960, UAB Research Education Program for Residents and Fellows in Neuroscience, G726287254, Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients

OpenAlex ID: W3132764055

FWCI: 0.71

Cites: 131

Cited by: 23

Related to: 10